Home Page - Slider
For Patients
Prepare for visits with your doctor or a genetic counselor by learning about testing.
Integrated Oncology Highlights
NEW test offering - OmniSeq Comprehensive next-gen molecular sequencing assay, identifying somatic variants in 144 genes. Learn more.
NEW test offering - The OmniSeq Immune Report Card assay supports immunotherapy treatment decision making by providing comprehensive immune profiling from a single sample. Learn more.
This test was recently FDA-approved as a complementary diagnostic assay that may help identify patients with locally advanced or metastatic urothelial carcinoma more likely to respond to treatment with TecentriqTM(atezolizumab).
Integrated Oncology now offers the FDA-approved cobas EGFR mutation test V2 in both FFPE tissue and plasma samples
This test was recently FDA-approved as a complementary diagnostic test to help physicians determine which patients may benefit most with OPDIVO® (nivolumab).
This test was recently FDA approved as a companion diagnostic assay to aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).
Every patient comes from a different background with a unique personal and family history. Patients with a family history that is specific to one cancer type may receive more benefit from a focused hereditary panel test. Integrated Oncology offers several cancer panel options for a more targeted approach to testing. Click here to view the press release.